NYSEAM:YMI - Post by User
Comment by
JuniorIOUon Aug 25, 2009 11:05am
440 Views
Post# 16247052
RE: Griffin Sec 5$US target
RE: Griffin Sec 5$US targetThis is the part Like :)
YMI SHARES REPRESENT EXCEPTIONAL VALUE. Given that the Company is trading near its cash balances of approximately $37 million as of March 31, 2009, nimotuzumab’s recent green light by the U.S. government for its development in the U.S., and the prospect of being best-in-class in an established and currently marketed class of billion dollar drugs, we believe the upside for the nimotuzumab asset and YMI is exceptional. Our valuation model supports a 12-month target price of $5.00 per share; therefore, we reiterate our BUY recommendation on YM BioSciences, Inc. and establish a new 12-month target price of $5.00 per share.